136 related articles for article (PubMed ID: 37715787)
1. Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Oya M; Kaneko S; Imai T; Tsujino T; Sunaya T; Okayama Y
Cancer Chemother Pharmacol; 2024 May; 93(5):523. PubMed ID: 37715787
[No Abstract] [Full Text] [Related]
2. Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Oya M; Kaneko S; Imai T; Tsujino T; Sunaya T; Okayama Y
Cancer Chemother Pharmacol; 2022 Jun; 89(6):761-772. PubMed ID: 35445315
[TBL] [Abstract][Full Text] [Related]
3. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib versus sorafenib for patients with advanced renal cell carcinoma with renal impairment before the immune-oncology therapy era.
Takayama T; Kubo T; Yamazaki M; Takeshima S; Komatsubara M; Kameda T; Kamei J; Sugihara T; Fujisaki A; Ando S; Kurokawa S; Fujimura T
Jpn J Clin Oncol; 2019 Dec; 49(12):1164-1171. PubMed ID: 31665407
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
van Doorn L; Eskens FA; Visser TJ; van der Lugt A; Mathijssen RH; Peeters RP
Thyroid; 2011 Feb; 21(2):197-202. PubMed ID: 21275767
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib-Induced Acute Pancreatitis in a Patient with Differentiated Thyroid Cancer.
Kattah Martinez LX; Marín Carrillo LF; Rojas Melo L
Eur Thyroid J; 2018 Jun; 7(3):145-148. PubMed ID: 30023347
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib: 10 years after the first pivotal trial.
Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.
Huang S; Li D; Zhuang L; Sun L; Wu J
World J Surg Oncol; 2021 Jun; 19(1):168. PubMed ID: 34112190
[TBL] [Abstract][Full Text] [Related]
11. The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis.
Cheng Z; He L; Guo Y; Song Y; Song S; Zhang L
World J Surg Oncol; 2020 Sep; 18(1):243. PubMed ID: 32917226
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract][Full Text] [Related]
13. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.
Abdel-Rahman O; Lamarca A
Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):75-83. PubMed ID: 27882800
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India.
Gupta N; Verma RK; Prinja S; Dhiman RK
J Clin Exp Hepatol; 2019; 9(4):468-475. PubMed ID: 31516263
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.
Dai L; Cai X; Mugaanyi J; Liu Y; Mao S; Lu C; Lu C
Sci Rep; 2021 Oct; 11(1):19711. PubMed ID: 34611195
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.
Horiuchi-Yamamoto Y; Gemma A; Taniguchi H; Inoue Y; Sakai F; Johkoh T; Fujimoto K; Kudoh S
Int J Clin Oncol; 2013 Aug; 18(4):743-9. PubMed ID: 22752255
[TBL] [Abstract][Full Text] [Related]
18. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
Marqueen KE; Kim E; Ang C; Mazumdar M; Buckstein M; Ferket BS
JCO Oncol Pract; 2021 Feb; 17(2):e266-e277. PubMed ID: 33417490
[TBL] [Abstract][Full Text] [Related]
20. Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Kong S; Yu H; Wang H; Song J; Yan J
Clin J Gastroenterol; 2023 Dec; 16(6):793-802. PubMed ID: 37740882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
